Trials / Withdrawn
WithdrawnNCT00352950
Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer
An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 954/Panitumumab |
Timeline
- Start date
- 2006-03-01
- Completion
- 2008-02-01
- First posted
- 2006-07-17
- Last updated
- 2018-09-06
Source: ClinicalTrials.gov record NCT00352950. Inclusion in this directory is not an endorsement.